Medication-assisted treatment with counseling and recovery support

Medication-assisted treatment with counseling and recovery support (MAT) is presented as an evidence-supported approach to opioid-use disorder that pairs medication with counseling and continuing recovery support. Its importance in the book lies not only in the improved outcomes associated with treatment, but in the distance between those outcomes and patients’ actual access to care: a person may need repeated treatment over many years, while cost, limited provider capacity, short detoxification programs, and opposition to medication interrupt the path.

A response to the limits of abstinence

The book sets MAT against a medical and commercial climate that helped expand opioid prescribing. When OxyContin appeared in 1996, medical institutions were adopting pain as the fifth vital sign and new standards for pain assessment and treatment. Purdue Pharma promoted the drug for a wide range of pain and presented addiction as rare. In 1999, the Joint Commission on Accreditation of Healthcare Organizations adopted mandatory pain-assessment and treatment standards; Purdue’s subsequent planning treated those requirements as an opportunity to supply hospitals with pain-management materials and position the company as an expert. Yet the numerical pain scales used to standardize care could make very different experiences register alike, and the book notes that reliance on such scales increased opioid prescribing and abuse without corresponding improvement in patient outcomes. MAT appears in this history as a treatment response to opioid dependence, not as a continuation of the claim that prescribing alone could safely resolve pain.

Abstinence-centered rehabilitation remained the norm even as evidence favored continued medication for opioid-use disorder. The book describes a persistent objection to treating addiction with another drug, including among some volunteers helping patients find care. Such resistance shaped what programs offered: Jesse Bolstridge, after entering rehabilitation in Jacksonville, received Buprenorphine treatment medication briefly, then was tapered off after three weeks in a program oriented toward abstinence. The account presents that short course as a consequential choice, not an equivalent substitute for ongoing maintenance.

Treatment and evidence

MAT may involve Methadone maintenance treatment drug, Buprenorphine treatment medication, or Vivitrol, alongside counseling and recovery support. The reported outcomes differ from those of abstinence-only care: fewer than one-quarter of people receiving abstinence-only counseling and support were reported to remain abstinent for two or more years, compared with roughly 40 to 60 percent among people receiving counseling, support groups, and medication-assisted treatment. An addiction specialist in the book also points to evidence from other countries that outcomes can exceed 50 percent when people remain in treatment. The comparison makes continuity central: medication is not presented as a stand-alone cure, but as part of sustained care.

The expected course can be lengthy. The book reports research indicating that it takes an average of about eight years from the start of treatment to achieve one year of sobriety, often over four or five treatment episodes. That timescale complicates judgments based on a single episode or a short-term lapse. National Institute on Drug Abuse director Nora Volkow states that the evidence supports long-term maintenance with medication in the context of behavioral treatment and recovery support, rather than brief detoxification intended to produce abstinence. The National Institute on Drug Abuse, the Institute of Medicine, the World Health Organization, and the White House drug czar’s office are described as supporting indefinite, potentially lifelong, maintenance. Hazelden Betty Ford Foundation, associated with the origins of the twenty-eight-day rehabilitation model, began offering Suboxone to some patients in 2012, a change that reflected a wider shift in institutional practice.

Access, cost, and uneven availability

Evidence of effectiveness did not mean that treatment was readily available. The book describes cash-only MAT clinics, rehabilitation programs that remained opposed to medication, and limited access to appropriate opioid-addiction care across the United States. The treatment journey could involve separate stages—finding a provider, meeting eligibility requirements, paying for visits, and obtaining continuing medication—with a break at any stage threatening continuity.

Tess Henry’s care illustrates the financial and geographic barriers. While pregnant, she entered the Life Center of Galax, one of the few Virginia facilities described as accepting patients already receiving medication-assisted treatment. She took the Subutex formulation without naloxone, then recommended for some pregnant patients. Private insurance covered most of the $20,000 treatment bill, while her father paid a $6,500 deductible from the remainder of Tess’s college savings. Later, insurance covered 80 percent of her medication, but her addiction doctor required $700 up front and charged $90 to $100 for each follow-up visit, sometimes as many as four in a month. The medication could prevent withdrawal and reduce cravings, but access to the prescriber who monitored and provided it remained costly.

Provider limits added another bottleneck. At the time, federal rules capped MAT-certified doctors at 100 patients; the cap was raised to 275 later that year. In 2017, access in Virginia began to broaden through the state response led in part by addiction specialist Hughes Melton. He made weekly flights between his Highpower clinic in Lebanon and his Richmond office, and worked with state Medicaid officials to broaden reimbursement, including payment for required counseling and care coordination. These changes encouraged some cash-only clinics to accept insurance, including Medicaid, although treatment needs still reached many communities faster than the new capacity did.

Connecting patients to continuing care

The book also documents attempts to make referrals more continuous. In early 2017, the Hope Initiative’s volunteers prepared a five-page spreadsheet listing 36 rehabilitation and aftercare providers across the southeastern United States. The list helped them seek a placement suited to a patient’s finances and the availability of beds. Some volunteers arranged outpatient MAT, but others were reluctant to endorse it. At the Bradley Free Clinic, people could meet trained volunteers on a monthly drop-in day to work through care arrangements; police checked for outstanding warrants, and eligible patients could receive help applying for Medicaid. The system offered a practical route into services, while also revealing how treatment depended on a patchwork of volunteer work, beds, eligibility, and payment.

A proposed emergency-room connection sought to reduce the gap between overdose treatment and outpatient medication. Researcher Warren Bickel received a $1 million grant to pilot procedures that would connect patients directly from emergency care to outpatient Buprenorphine treatment medication, including through the newly approved once-monthly injection Sublocade. His argument for adequate rather than punitive dosing followed a case in which a patient’s medication had been reduced after a follow-up test showed additional opioid use. In Roanoke, the community services board had added MAT for 21 patients, conditional on counseling, while Carilion still had a three-week wait for outpatient treatment. The contrast between a new transfer model and those local limits shows why an effective medication alone could not guarantee timely care.

Significance

MAT gives the book a way to distinguish treatment evidence from treatment delivery. Its reported advantages over abstinence-only care are substantial, but the cases show that those advantages depend on staying in treatment and on services being affordable, available, and connected. Short tapers, waiting lists, cash requirements, provider caps, and institutional resistance can all turn a recommended long-term approach into a brief or interrupted encounter. The recurring question is therefore not simply whether medication works, but whether a system can keep people connected to it long enough for recovery support and treatment to take effect.